Pediatric RSV Vaccine Safety Casts A ‘Long Shadow’ For US FDA

 
• By Michael McCaughan

The US FDA faces many communications challenges with vaccine skepticism rampant. Is doing everything right going to be good enough?

The VRBPAC's message that safeguards were effective in pediatric vaccine trials may not be the last word on the subject. (Shutterstock)

More from Vaccines

More from Pathways & Standards